Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.69 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.66 |
| ▸ | RXRA | P19793 | 2/20 | 0.62 |
| ▸ | RXRB | P28702 | 2/20 | 0.62 |
| ▸ | AHR | P35869 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KMO | O15229 | 2/20 | 0.58 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.52 |
| ▸ | BAD | Q92934 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | RPA1 | P27694 | 1/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637495 | 1.00 | TSHR (0.69) | TSHRSRD5A2RXRARXRBAHR | |
| SCHEMBL30784621 | 0.84 | XDH (0.60) | TSHRSRD5A2RXRARXRBKDM4E | |
| SCHEMBL18688873 | 0.84 | XDH (0.60) | TSHRSRD5A2RXRARXRBKDM4E | |
| SCHEMBL23484544 | 0.83 | AHR (0.58) | TSHRSRD5A2AHRKDM4EMEN1 | |
| SCHEMBL3540530 | 0.82 | KMO (0.66) | TSHRRXRARXRBAHRKDM4E | |
| SCHEMBL8662676 | 0.82 | ESR2 (0.61) | TSHRSRD5A2RXRARXRBKDM4E | |
| SCHEMBL3643412 | 0.82 | RXRA (0.61) | TSHRSRD5A2RXRARXRBKDM4E | |
| SCHEMBL18530501 | 0.82 | RXRA (0.56) | TSHRSRD5A2RXRARXRBKDM4E | |
| SCHEMBL8352471 | 0.82 | TSHR (1.00) | TSHRSRD5A2KDM4EMEN1NPC1 | |
| SCHEMBL371998 | 0.82 | TSHR (1.00) | TSHRSRD5A2KDM4EMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | TSHR 3028/4885SRD5A2 4796/4885RXRA 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.